Precision medicine: Clarity for the complexity of dementia

American Journal of Pathology

Volumn 186, Issue 3, 2016, Pages 500-506

  Cholerton, Brenna ^a   Larson, Eric B ^c   Quinn, Joseph F ^d,e   Zabetian, Cyrus P ^b,f   Mata, Ignacio F ^b,f   Keene, C Dirk ^b   Flanagan, Margaret ^b   Crane, Paul K ^b   Grabowski, Thomas J ^a,b   Montine, Kathleen S ^b   Montine, Thomas J ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e PORTLAND VA MEDICAL CENTER   (United States)

^f VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; HUMAN; PARKINSON DISEASE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RARE DISEASE; REVIEW; GENETICS; MUTATION; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; COGNITION DISORDERS; DEMENTIA; HUMANS; MUTATION; PARKINSON DISEASE; PRECISION MEDICINE;

EID: 84959019693     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2015.12.001     Document Type: Review

References (56)

1. T.J. Montine, and K.S. Montine Precision medicine: clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases J Exp Med 212 2015 601 605
2. C.E. Wainwright, J.S. Elborn, B.W. Ramsey, G. Marigowda, X. Huang, M. Cipolli, C. Colombo, J.C. Davies, K. De Boeck, P.A. Flume, M.W. Konstan, S.A. McColley, K. McCoy, E.F. McKone, A. Munck, F. Ratjen, S.M. Rowe, D. Waltz, and M.P. Boyle Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR N Engl J Med 373 2015 220 231
3. Global Burden of Disease Study 2013 Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 386 2015 743 800
4. GBD 2013 Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 385 2015 117 171
5. J.A. Sonnen, K. Santa Cruz, L.S. Hemmy, R. Woltjer, J.B. Leverenz, K.S. Montine, C.R. Jack, J. Kaye, K. Lim, E.B. Larson, L. White, and T.J. Montine Ecology of the aging human brain Arch Neurol 68 2011 1049 1056
6. J.A. Sonnen, E.B. Larson, S. Haneuse, R. Woltjer, G. Li, P.K. Crane, S. Craft, and T.J. Montine Neuropathology in the adult changes in thought study: a review J Alzheimers Dis 18 2009 703 711
7. V. Haroutunian, M. Serby, D.P. Purohit, D.P. Perl, D. Marin, M. Lantz, R.C. Mohs, and K.L. Davis Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions Arch Neurol 57 2000 1145 1150
8. EClipSE Collaborative Members Cohort profile: epidemiological clinicopathological studies in Europe (EClipSE) J Alzheimers Dis 18 2009 659 663
9. C. Brayne, K. Richardson, F.E. Matthews, J. Fleming, S. Hunter, J.H. Xuereb, E. Paykel, E.B. Mukaetova-Ladinska, F.A. Huppert, A. O'Sullivan, and T. Dening Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s cohort (CC75C) study J Alzheimers Dis 18 2009 645 658
10. R.J. O'Brien, S.M. Resnick, A.B. Zonderman, L. Ferrucci, B.J. Crain, O. Pletnikova, G. Rudow, D. Iacono, M.A. Riudavets, I. Driscoll, D.L. Price, L.J. Martin, and J.C. Troncoso Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA) J Alzheimers Dis 18 2009 665 675
11. L. Yu, P.A. Boyle, S. Leurgans, J.A. Schneider, R.J. Kryscio, R.S. Wilson, and D.A. Bennett Effect of common neuropathologies on progression of late life cognitive impairment Neurobiol Aging 36 2015 2225 2231
12. P.T. Nelson, E.L. Abner, F.A. Schmitt, R.J. Kryscio, G.A. Jicha, C.D. Smith, D.G. Davis, J.W. Poduska, E. Patel, M.S. Mendiondo, and W.R. Markesbery Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons Brain Pathol 20 2010 66 79
13. J.A. Sonnen, E.B. Larson, P.K. Crane, S. Haneuse, G. Li, G.D. Schellenberg, S. Craft, J.B. Leverenz, and T.J. Montine Pathological correlates of dementia in a longitudinal, population-based sample of aging Ann Neurol 62 2007 406 413
14. T.J. Montine, W.J. Koroshetz, D. Babcock, D.W. Dickson, W.R. Galpern, M.M. Glymour, S.M. Greenberg, M.L. Hutton, D.S. Knopman, A.N. Kuzmichev, J.J. Manly, K.S. Marder, B.L. Miller, C.H. Phelps, W.W. Seeley, B.A. Sieber, N.B. Silverberg, M. Sutherland, C.L. Torborg, S.P. Waddy, B.V. Zlokovic, and R.A. Corriveau Recommendations of the Alzheimer's disease-related dementias conference Neurology 83 2014 851 860
15. G.J. Geurtsen, J. Hoogland, J.G. Goldman, B.A. Schmand, A.I. Troster, D.J. Burn, and I. Litvan Parkinson's disease mild cognitive impairment: application and validation of the criteria J Parkinsons Dis 4 2014 131 137
16. C.F. Lippa, J.E. Duda, M. Grossman, H.I. Hurtig, D. Aarsland, B.F. Boeve, D.J. Brooks, D.W. Dickson, B. Dubois, M. Emre, S. Fahn, J.M. Farmer, D. Galasko, J.E. Galvin, C.G. Goetz, J.H. Growdon, K.A. Gwinn-Hardy, J. Hardy, P. Heutink, T. Iwatsubo, K. Kosaka, V.M. Lee, J.B. Leverenz, E. Masliah, I.G. McKeith, R.L. Nussbaum, C.W. Olanow, B.M. Ravina, A.B. Singleton, C.M. Tanner, J.Q. Trojanowski, and Z.K. Wszolek DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers Neurology 68 2007 812 819
17. B.T. Hyman, C.H. Phelps, T.G. Beach, E.H. Bigio, N.J. Cairns, M.C. Carrillo, D.W. Dickson, C. Duyckaerts, M.P. Frosch, E. Masliah, S.S. Mirra, P.T. Nelson, J.A. Schneider, D.R. Thal, B. Thies, J.Q. Trojanowski, H.V. Vinters, and T.J. Montine National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease Alzheimers Dement 8 2012 1 13
18. T.J. Montine, C.H. Phelps, T.G. Beach, E.H. Bigio, N.J. Cairns, D.W. Dickson, C. Duyckaerts, M.P. Frosch, E. Masliah, S.S. Mirra, P.T. Nelson, J.A. Schneider, D.R. Thal, J.Q. Trojanowski, H.V. Vinters, and B.T. Hyman National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach Acta Neuropathol 123 2012 1 11
19. E. Stefanova, L. Ziropadja, T. Stojkovic, I. Stankovic, A. Tomic, M. Jecmenica-Lukic, I. Petrovic, and V. Kostic Mild cognitive impairment in early Parkinson's disease using the Movement Disorder Society Task Force criteria: cross-sectional study in Hoehn and Yahr stage 1 Dement Geriatr Cogn Disord 40 2015 199 209
20. R. Mayeux, J. Denaro, N. Hemenegildo, K. Marder, M.X. Tang, L.J. Cote, and Y. Stern A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender Arch Neurol 49 1992 492 497
21. D. Aarsland, E. Tandberg, J.P. Larsen, and J.L. Cummings Frequency of dementia in Parkinson disease Arch Neurol 53 1996 538 542
22. P. Hobson, and J. Meara Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom Mov Disord 19 2004 1043 1049
23. T.C. Buter, A. van den Hout, F.E. Matthews, J.P. Larsen, C. Brayne, and D. Aarsland Dementia and survival in Parkinson disease: a 12-year population study Neurology 70 2008 1017 1022
24. M.E. Domellof, U. Ekman, L. Forsgren, and E. Elgh Cognitive function in the early phase of Parkinson's disease, a five-year follow-up Acta Neurol Scand 132 2015 79 88
25. P. Hobson, and J. Meara Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort Int J Geriatr Psychiatry 30 2015 1048 1055
26. B.A. Cholerton, C.P. Zabetian, J.F. Quinn, K.A. Chung, A. Peterson, A.J. Espay, F.J. Revilla, J. Devoto, G.S. Watson, S.C. Hu, K.L. Edwards, T.J. Montine, and J.B. Leverenz Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics J Parkinsons Dis 3 2013 205 214
27. J. Raskin, J. Cummings, J. Hardy, K. Schuh, and R.A. Dean Neurobiology of Alzheimer's disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions Curr Alzheimer Res 12 2015 712 722
28. N. Postupna, C.D. Keene, P.K. Crane, L.F. Gonzalez-Cuyar, J.A. Sonnen, J. Hewitt, S. Rice, K. Howard, K.S. Montine, E.B. Larson, and T.J. Montine Cerebral cortical Abeta42 and PHF-tau in 325 consecutive brain autopsies stratified by diagnosis, location, and APOE J Neuropathol Exp Neurol 74 2015 100 109
29. N. Postupna, S.E. Rose, T.D. Bird, L.F. Gonzalez-Cuyar, J.A. Sonnen, E.B. Larson, C.D. Keene, and T.J. Montine Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults Brain Pathol 22 2012 472 484
30. J.C. Lambert, C.A. Ibrahim-Verbaas, D. Harold, A.C. Naj, R. Sims, C. Bellenguez, and et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease Nat Genet 45 2013 1452 1458
31. V. Escott-Price, C. Bellenguez, L.S. Wang, S.H. Choi, D. Harold, L. Jones, and et al. Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease PLoS One 9 2014 e94661
32. G. Jun, C.A. Ibrahim-Verbaas, M. Vronskaya, J.C. Lambert, J. Chung, A.C. Naj, and et al. A novel Alzheimer disease locus located near the gene encoding tau protein Mol Psychiatry 2015 21 2016 108 117
33. M.A. Nalls, V. Plagnol, D.G. Hernandez, M. Sharma, U.M. Sheerin, M. Saad, J. Simon-Sanchez, C. Schulte, S. Lesage, S. Sveinbjornsdottir, K. Stefansson, M. Martinez, J. Hardy, P. Heutink, A. Brice, T. Gasser, A.B. Singleton, and N.W. Wood Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies Lancet 377 2011 641 649
34. C.M. Lill, J.T. Roehr, M.B. McQueen, F.K. Kavvoura, S. Bagade, B.M. Schjeide, and et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database PLoS Genet 8 2012 e1002548
35. G.W. Beecham, D.W. Dickson, W.K. Scott, E.R. Martin, G. Schellenberg, K. Nuytemans, E.B. Larson, J.D. Buxbaum, J.Q. Trojanowski, V.M. Van Deerlin, H.I. Hurtig, D.C. Mash, T.G. Beach, J.C. Troncoso, O. Pletnikova, M.P. Frosch, B. Ghetti, T.M. Foroud, L.S. Honig, K. Marder, J.P. Vonsattel, S.M. Goldman, H.V. Vinters, O.A. Ross, Z.K. Wszolek, L. Wang, D.M. Dykxhoorn, M.A. Pericak-Vance, T.J. Montine, J.B. Leverenz, T.M. Dawson, and J.M. Vance PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease Neurology 84 2015 972 980
36. I.F. Mata, J.B. Leverenz, D. Weintraub, J.Q. Trojanowski, H.I. Hurtig, V.M. Van Deerlin, B. Ritz, R. Rausch, S.L. Rhodes, S.A. Factor, C. Wood-Siverio, J.F. Quinn, K.A. Chung, A.L. Peterson, A.J. Espay, F.J. Revilla, J. Devoto, S.C. Hu, B.A. Cholerton, J.Y. Wan, T.J. Montine, K.L. Edwards, and C.P. Zabetian APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease JAMA Neurol 71 2014 1405 1412
37. S. Srivatsal, B. Cholerton, J.B. Leverenz, Z.K. Wszolek, R.J. Uitti, D.W. Dickson, D. Weintraub, J.Q. Trojanowski, V.M. Van Deerlin, J.F. Quinn, K.A. Chung, A.L. Peterson, S.A. Factor, C. Wood-Siverio, J.G. Goldman, G.T. Stebbins, B. Bernard, B. Ritz, R. Rausch, A.J. Espay, F.J. Revilla, J. Devoto, L.S. Rosenthal, T.M. Dawson, M.S. Albert, I.F. Mata, S.C. Hu, K.S. Montine, C. Johnson, T.J. Montine, K.L. Edwards, J. Zhang, and C.P. Zabetian Cognitive profile of LRRK2-related Parkinson's disease Mov Disord 30 2015 728 733
38. Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP: GBA variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 2015, [Epub ahead of print]. doi: 10.1002/mds.26359.
39. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D.P. Holt, M. Bergstrom, I. Savitcheva, G.F. Huang, S. Estrada, B. Ausen, M.L. Debnath, J. Barletta, J.C. Price, J. Sandell, B.J. Lopresti, A. Wall, P. Koivisto, G. Antoni, C.A. Mathis, and B. Langstrom Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 2004 306 319
40. V.L. Villemagne, M.T. Fodero-Tavoletti, C.L. Masters, and C.C. Rowe Tau imaging: early progress and future directions Lancet Neurol 14 2015 114 124
41. R. Motter, C. Vigo-Pelfrey, D. Kholodenko, R. Barbour, K. Johnson-Wood, D. Galasko, L. Chang, B. Miller, C. Clark, R. Green, D. Olson, P. Southwick, R. Wolfert, B. Munroe, I. Lieberburg, P. Seubert, and D. Schenk Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease Ann Neurol 38 1995 643 648
42. D. Galasko, C. Clark, L. Chang, B. Miller, R.C. Green, R. Motter, and P. Seubert Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease Neurology 48 1997 632 635
43. H. Arai, Y. Morikawa, M. Higuchi, T. Matsui, C.M. Clark, M. Miura, N. Machida, V.M. Lee, J.Q. Trojanowski, and H. Sasaki Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology Biochem Biophys Res Commun 236 1997 262 264
44. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, J. Cedarbaum, M.C. Donohue, R.C. Green, D. Harvey, C.R. Jack Jr., W. Jagust, J.C. Morris, R.C. Petersen, A.J. Saykin, L. Shaw, P.M. Thompson, A.W. Toga, and J.Q. Trojanowski Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 Alzheimers Dement 11 2015 865 884
45. T. Skillback, B.Y. Farahmand, C. Rosen, N. Mattsson, K. Nagga, L. Kilander, D. Religa, A. Wimo, B. Winblad, J.M. Schott, K. Blennow, M. Eriksdotter, and H. Zetterberg Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia Brain 138 Pt 9 2015 2716 2731
46. J.H. Kang, D.J. Irwin, A.S. Chen-Plotkin, A. Siderowf, C. Caspell, C.S. Coffey, T. Waligorska, P. Taylor, S. Pan, M. Frasier, K. Marek, K. Kieburtz, D. Jennings, T. Simuni, C.M. Tanner, A. Singleton, A.W. Toga, S. Chowdhury, B. Mollenhauer, J.Q. Trojanowski, and L.M. Shaw Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease JAMA Neurol 70 2013 1277 1287
47. The Parkinson Progression Marker Initiative (PPMI) Prog Neurobiol 95 2011 629 635
48. M. Niethammer, C.C. Tang, Y. Ma, P.J. Mattis, J.H. Ko, V. Dhawan, and D. Eidelberg Parkinson's disease cognitive network correlates with caudate dopamine Neuroimage 78 2013 204 209
49. D.J. Brooks Imaging dopamine transporters in Parkinson's disease Biomark Med 4 2010 651 660
50. D.C. Backstrom, M. Eriksson Domellof, J. Linder, B. Olsson, A. Ohrfelt, M. Trupp, H. Zetterberg, K. Blennow, and L. Forsgren Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease JAMA Neurol 72 2015 1175 1182
51. J.B. Toledo, A. Korff, L.M. Shaw, J.Q. Trojanowski, and J. Zhang CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease Acta Neuropathol 126 2013 683 697
52. B.A. Sieber, S. Landis, W. Koroshetz, R. Bateman, A. Siderowf, W.R. Galpern, J. Dunlop, S. Finkbeiner, M. Sutherland, H. Wang, V.M. Lee, H.T. Orr, K. Gwinn, K. Ludwig, A. Taylor, C. Torborg, and T.J. Montine Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference Ann Neurol 76 2014 469 472
53. J.H. Kang, N.Y. Ryoo, D.W. Shin, J.Q. Trojanowski, and L.M. Shaw Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies Korean J Physiol Pharmacol 18 2014 447 456
54. S.M. Mills, J. Mallmann, A.M. Santacruz, A. Fuqua, M. Carril, P.S. Aisen, and et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial Rev Neurol (Paris) 169 2013 737 743
55. E.M. Reiman, J.B. Langbaum, A.S. Fleisher, R.J. Caselli, K. Chen, N. Ayutyanont, Y.T. Quiroz, K.S. Kosik, F. Lopera, and P.N. Tariot Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments J Alzheimers Dis 26 Suppl 3 2011 321 329
56. R.A. Sperling, D.M. Rentz, K.A. Johnson, J. Karlawish, M. Donohue, D.P. Salmon, and P. Aisen The A4 study: stopping AD before symptoms begin? Sci Transl Med 6 2014 228fs13